Transplant patients get new hope: sirolimus cream may stop facial cancers
NCT ID NCT05860881
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 trial tests whether a cream containing sirolimus (rapamycin) can prevent facial skin cancers in people who have received an organ transplant. 146 participants apply the cream or a placebo to their face every night for 6 months. The study counts new skin cancers during treatment and up to 2 years later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (rapamycin) cream
What this could lead to
If it works, this could offer a way to reduce skin cancer risk in organ transplant recipients without needing more surgery.
What could go wrong
This is a phase 3 trial, but results are not yet available. The cream may cause skin irritation or not reduce cancer risk significantly. Transplant recipients already take lifelong immunosuppressants, which may limit the effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Alexandra Hospital
Woolloongabba, Queensland, 4102, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
Skin Health Institute
Carlton, Victoria, 3053, Australia
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
-
The Prince Charles Hospital
Chermside, Queensland, 4032, Australia
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia